September 11, 2017 / 2:13 PM / in a month

BRIEF-Diamedica announces the initiation of phase 2 trial evaluating DM199 (Recombinant Human KLK1) in patients with acute ischemic stroke

Sept 11 (Reuters) - Diamedica Therapeutics Inc

* Diamedica announces the initiation of phase 2 trial evaluating DM199 (recombinant human Klk1) in patients with acute ischemic stroke Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below